Tarlatamab trials for Extensive-stage Small-cell Lung Cancer

All Tarlatamab trials · All Extensive-stage Small-cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Tarlatamab for Extensive-stage Small-cell Lung Cancer

• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
  NCT07037758 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 19 locations
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations

Common questions

How many trials study Tarlatamab for Extensive-stage Small-cell Lung Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.